Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Grant and contract revenue	$ 2,112,806	$ 2,947,969
Operating expenses:
Research and development	18,821,278	12,938,895
General and administrative	16,828,229	14,934,436
Goodwill impairment loss	(1,452,338)	0
Change in fair value of contingent consideration	430,000	1,199,000
Total operating expenses	37,531,845	29,072,331
Loss from operations	(35,419,039)	(26,124,362)
Change in fair value of warrant liability	22,758	(1,012,167)
Investor relations expense		(66,767)
Interest income	815,316	566,718
Other (expense) income, net	(965,816)	255,189
Total non-operating income (loss)	(127,742)	(257,027)
Net loss before income taxes	(35,546,781)	(26,381,389)
Income tax expense	145,974
Net loss	(35,400,807)	(26,381,389)
Net loss - non-controlling interest	(329,339)	(331,652)
Net loss attributable to Heat Biologics, Inc.	$ (35,071,468)	$ (26,049,737)
Net loss per share, basic (in dollars per share)	$ (1.41)	$ (1.63)
Net loss per share, diluted (in dollars per share)	$ (1.49)	$ (1.63)
Weighted-average common shares outstanding, basic (in shares)	24,913,942	15,982,568
Weighted-average common shares outstanding, diluted (in shares)	24,913,942	15,982,568
Comprehensive loss:
Net loss	$ (35,400,807)	$ (26,381,389)
Unrealized gain (loss) on foreign currency translation	98,115	(154,806)
Total comprehensive loss	(35,302,692)	(26,536,195)
Comprehensive loss attributable to non-controlling interest	(329,339)	(331,652)
Comprehensive loss - Heat Biologics, Inc.	$ (34,973,353)	$ (26,204,543)